{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:50:43Z","timestamp":1787003443225,"version":"build-2736575974"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Oral vaccines aid immunization of hard to reach animal populations but often contain live-attenuated viruses that pose risks of reversion to virulence or residual pathogenicity. Human risk assessment is crucial prior to vaccine field distribution but there is currently no standardized approach. We mapped exposure pathways by which distribution of oral vaccines may result in inoculation into people and applied a Markov chain to estimate the number of severe adverse events. We simulated three oral rabies vaccination (ORV) campaigns: (1) first generation ORV (SAD-B19) in foxes, (2) SAD-B19 in dogs, and (3) third generation ORV (SPBN GASGAS) in dogs. The risk of SAD-B19-associated human deaths was predicted to be low (0.18 per 10 million baits, 95% CI: 0.08, 0.36) when distributed to foxes, but, consistent with international concern, 19 times greater (3.35 per 10 million baits, 95% CI: 2.83, 3.98) when distributed to dogs. We simulated no deaths from SPBN GAS-GAS. Human deaths during dog campaigns were particularly sensitive to dog bite rate, and during wildlife campaigns to animal consumption rate and human contact rate with unconsumed baits. This model highlights the safety of third generation rabies vaccines and serves as a platform for standardized approaches to inform risk assessments.<\/jats:p>","DOI":"10.1038\/s41598-019-42714-9","type":"journal-article","created":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T06:02:54Z","timestamp":1556690574000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Environmental distribution of certain modified live-virus vaccines with a high safety profile presents a low-risk, high-reward to control zoonotic diseases"],"prefix":"10.1038","volume":"9","author":[{"given":"Jennifer R.","family":"Head","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ad","family":"Vos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2634-355X","authenticated-orcid":false,"given":"Jesse","family":"Blanton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0959-3653","authenticated-orcid":false,"given":"Thomas","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Chipman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily G.","family":"Pieracci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Cleaton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Wallace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,1]]},"reference":[{"key":"42714_CR1","doi-asserted-by":"publisher","unstructured":"Jones, K. E. et al. Global trends in emerging infectious diseases. Nature 451, 990, https:\/\/doi.org\/10.1038\/nature06536 https:\/\/www.nature.com\/articles\/nature06536#supplementary-information (2008).","DOI":"10.1038\/nature06536"},{"key":"42714_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s12917-018-1417-0","volume":"14","author":"S Ortmann","year":"2018","unstructured":"Ortmann, S. et al. Safety studies with the oral rabies virus vaccine strain SPBN GASGAS in the small Indian mongoose (Herpestes auropunctatus). BMC Veterinary Research 14, 90, https:\/\/doi.org\/10.1186\/s12917-018-1417-0 (2018).","journal-title":"BMC Veterinary Research"},{"key":"42714_CR3","doi-asserted-by":"publisher","first-page":"2987","DOI":"10.1098\/rspb.2009.0414","volume":"276","author":"DM Tompkins","year":"2009","unstructured":"Tompkins, D. M. et al. Oral vaccination reduces the incidence of tuberculosis in free-living brushtail possums. Proceedings of the Royal Society B: Biological Sciences 276, 2987\u20132995, https:\/\/doi.org\/10.1098\/rspb.2009.0414 (2009).","journal-title":"Proceedings of the Royal Society B: Biological Sciences"},{"key":"42714_CR4","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.tvjl.2006.10.005","volume":"174","author":"ML Cross","year":"2007","unstructured":"Cross, M. L., Buddle, B. M. & Aldwell, F. E. The potential of oral vaccines for disease control in wildlife species. The Veterinary Journal 174, 472\u2013480, https:\/\/doi.org\/10.1016\/j.tvjl.2006.10.005 (2007).","journal-title":"The Veterinary Journal"},{"key":"42714_CR5","doi-asserted-by":"publisher","unstructured":"Freuling, C. M. et al. Efficacy of the oral rabies virus vaccine strain SPBN GASGAS in foxes and raccoon dogs. Vaccine, https:\/\/doi.org\/10.1016\/j.vaccine.2017.09.093 (2017).","DOI":"10.1016\/j.vaccine.2017.09.093"},{"key":"42714_CR6","doi-asserted-by":"publisher","unstructured":"Cossaboom C. M. et al. Notes from the Field: Brucella abortus Vaccine Strain RB51 Infection and Exposures Associated with Raw Milk Consumption \u2014 Wise County, Texas, 2017. MMWR. Morbidity and mortality weekly report 67, https:\/\/doi.org\/10.15585\/mmwr.mm6709a4 (2018).","DOI":"10.15585\/mmwr.mm6709a4"},{"key":"42714_CR7","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1586\/erv.11.79","volume":"10","author":"SR Walsh","year":"2011","unstructured":"Walsh, S. R. & Dolin, R. Vaccinia viruses: vaccines against smallpox and vectors against infectious diseases and tumors. Expert review of vaccines 10, 1221\u20131240, https:\/\/doi.org\/10.1586\/erv.11.79 (2011).","journal-title":"Expert review of vaccines"},{"key":"42714_CR8","doi-asserted-by":"publisher","first-page":"e0185594","DOI":"10.1371\/journal.pone.0185594","volume":"12","author":"L Ferreyra-Reyes","year":"2017","unstructured":"Ferreyra-Reyes, L. et al. Assessing the individual risk of fecal poliovirus shedding among vaccinated and non-vaccinated subjects following national health weeks in Mexico. PloS one 12, e0185594\u2013e0185594, https:\/\/doi.org\/10.1371\/journal.pone.0185594 (2017).","journal-title":"PloS one"},{"key":"42714_CR9","doi-asserted-by":"crossref","unstructured":"Freuling, C. M. et al. The elimination of fox rabies from Europe: Determinants of success and lessons for the future. Vol. 368 (2013).","DOI":"10.1098\/rstb.2012.0142"},{"key":"42714_CR10","first-page":"195","volume":"1012","author":"World Health Organization","year":"2018","unstructured":"World Health Organization. WHO expert consultation on rabies, third report. World Health Organ Tech Rep Ser 1012, 195 (2018).","journal-title":"World Health Organ Tech Rep Ser"},{"key":"42714_CR11","doi-asserted-by":"publisher","unstructured":"Pfaff, F. et al. In-depth genome analyses of viruses from vaccine-derived rabies cases and corresponding live-attenuated oral rabies vaccines. Vaccine, https:\/\/doi.org\/10.1016\/j.vaccine.2018.01.083 (2018).","DOI":"10.1016\/j.vaccine.2018.01.083"},{"key":"42714_CR12","doi-asserted-by":"publisher","first-page":"7194","DOI":"10.1073\/pnas.81.22.7194","volume":"81","author":"TJ Wiktor","year":"1984","unstructured":"Wiktor, T. J. et al. Protection from rabies by a vaccinia virus recombinant containing the rabies virus glycoprotein gene. Proceedings of the National Academy of Sciences of the United States of America 81, 7194\u20137198 (1984).","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"42714_CR13","doi-asserted-by":"crossref","unstructured":"Yarosh, O. K., Wandeler, A. I., Graham, F. L., Campbell, J. B. & Prevec, L. Human adenovirus type 5 vectors expressing rabies glycoprotein. Vaccine. Vol. 14 (1996).","DOI":"10.1016\/S0264-410X(96)00012-6"},{"key":"42714_CR14","doi-asserted-by":"crossref","unstructured":"Artois, M. et al. Potential pathogenicity for rodents of vaccines intended for oral vaccination against rabies: a comparison. Vaccine. Vol. 10 (1992).","DOI":"10.1016\/0264-410X(92)90351-J"},{"key":"42714_CR15","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1017\/S0950268899002666","volume":"123","author":"A Vos","year":"1999","unstructured":"Vos, A. et al. An update on safety studies of SAD B19 rabies virus vaccine in target and non-target species. Epidemiol Infect 123, 165\u2013175 (1999).","journal-title":"Epidemiol Infect"},{"key":"42714_CR16","first-page":"315","volume":"38","author":"LG Schneider","year":"1983","unstructured":"Schneider, L. G. & Cox, J. H. Ein Fedelversuch zur oralen Immunisierung von F\u00fcchsen gegen die Tollwut in der Bundesrepublik Deutschland. Tier\u00e4rztl. Umsch. 38, 315\u2013324 (1983).","journal-title":"Tier\u00e4rztl. Umsch."},{"key":"42714_CR17","doi-asserted-by":"publisher","first-page":"71","DOI":"10.7589\/0090-3558-44.1.71","volume":"44","author":"C Fehlner-Gardiner","year":"2008","unstructured":"Fehlner-Gardiner, C. et al. Era vaccine-derived cases of rabies in wildlife and domestic animals in Ontario, Canada, 1989-2004. Journal of wildlife diseases 44, 71\u201385, https:\/\/doi.org\/10.7589\/0090-3558-44.1.71 (2008).","journal-title":"Journal of wildlife diseases"},{"key":"42714_CR18","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1007\/s00705-009-0408-7","volume":"154","author":"T M\u00fcller","year":"2009","unstructured":"M\u00fcller, T. et al. Analysis of vaccine-virus-associated rabies cases in red foxes (Vulpes vulpes) after oral rabies vaccination campaigns in Germany and Austria. Archives of virology 154, 1081\u20131091, https:\/\/doi.org\/10.1007\/s00705-009-0408-7 (2009).","journal-title":"Archives of virology"},{"key":"42714_CR19","doi-asserted-by":"publisher","first-page":"397","DOI":"10.7589\/2013-07-183","volume":"50","author":"P Hostnik","year":"2014","unstructured":"Hostnik, P., Picard-Meyer, E., Rihtaric, D., Toplak, I. & Cliquet, F. Vaccine-induced rabies in a red fox (Vulpes vulpes): isolation of vaccine virus in brain tissue and salivary glands. Journal of wildlife diseases 50, 397\u2013401, https:\/\/doi.org\/10.7589\/2013-07-183 (2014).","journal-title":"Journal of wildlife diseases"},{"key":"42714_CR20","doi-asserted-by":"publisher","first-page":"5021","DOI":"10.1016\/j.vaccine.2016.08.013","volume":"34","author":"V Vuta","year":"2016","unstructured":"Vuta, V. et al. Vaccine-induced rabies case in a cow (Bos taurus): Molecular characterisation of vaccine strain in brain tissue. Vaccine 34, 5021\u20135025, https:\/\/doi.org\/10.1016\/j.vaccine.2016.08.013 (2016).","journal-title":"Vaccine"},{"key":"42714_CR21","doi-asserted-by":"crossref","unstructured":"Andreas R. K. & Hildegund C.J. E. Rabies Vaccines: From the Past to the 21st Century. Vol. 21 (2002).","DOI":"10.1089\/153685902317401726"},{"key":"42714_CR22","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1073\/pnas.80.1.70","volume":"80","author":"B Dietzschold","year":"1983","unstructured":"Dietzschold, B. et al. Characterization of an antigenic determinant of the glycoprotein that correlates with pathogenicity of rabies virus. Proceedings of the National Academy of Sciences of the United States of America 80, 70\u201374 (1983).","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"42714_CR23","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1016\/S0264-410X(96)00114-4","volume":"14","author":"E Masson","year":"1996","unstructured":"Masson, E. et al. Safety study of the SAG2 rabies virus mutant in several non-target species with a view to its future use for the immunization of foxes in Europe. Vaccine 14, 1506\u20131510, https:\/\/doi.org\/10.1016\/S0264-410X(96)00114-4 (1996).","journal-title":"Vaccine"},{"key":"42714_CR24","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1099\/0022-1317-48-1-105","volume":"48","author":"A Flamand","year":"1980","unstructured":"Flamand, A., Wiktor, T. J. & Koprowski, H. Use of hybridoma monoclonal antibodies in the detection of antigenic differences between rabies and rabies-related virus proteins. II. The glycoprotein. The Journal of general virology 48, 105\u2013109, https:\/\/doi.org\/10.1099\/0022-1317-48-1-105 (1980).","journal-title":"The Journal of general virology"},{"key":"42714_CR25","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/0042-6822(90)90433-R","volume":"175","author":"KH Conzelmann","year":"1989","unstructured":"Conzelmann, K. H., Cox, J. H., Schneider, L. G. & Thiel, H. J. Molecular Cloning and Complete Nucleotide Sequence of the Attenuated Rabies Virus SAD B19. Virology 175, 485\u2013499 (1989).","journal-title":"Virology"},{"key":"42714_CR26","doi-asserted-by":"publisher","first-page":"14141","DOI":"10.1128\/jvi.79.22.14141-14148.2005","volume":"79","author":"M Faber","year":"2005","unstructured":"Faber, M. et al. A Single Amino Acid Change in Rabies Virus Glycoprotein Increases Virus Spread and Enhances Virus Pathogenicity. Journal of Virology 79, 14141\u201314148, https:\/\/doi.org\/10.1128\/jvi.79.22.14141-14148.2005 (2005).","journal-title":"Journal of Virology"},{"key":"42714_CR27","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.vaccine.2007.10.072","volume":"26","author":"J Li","year":"2008","unstructured":"Li, J., McGettigan, J. P., Faber, M., Schnell, M. J. & Dietzschold, B. Infection of monocytes or immature dendritic cells (DCs) with an attenuated rabies virus results in DC maturation and a strong activation of the NF\u03baB signaling pathway. Vaccine 26, 419\u2013426, https:\/\/doi.org\/10.1016\/j.vaccine.2007.10.072 (2008).","journal-title":"Vaccine"},{"key":"42714_CR28","doi-asserted-by":"publisher","first-page":"3374","DOI":"10.1128\/jvi.76.7.3374-3381.2002","volume":"76","author":"M Faber","year":"2002","unstructured":"Faber, M. et al. Overexpression of the Rabies Virus Glycoprotein Results in Enhancement of Apoptosis and Antiviral Immune Response. Journal of Virology 76, 3374\u20133381, https:\/\/doi.org\/10.1128\/jvi.76.7.3374-3381.2002 (2002).","journal-title":"Journal of Virology"},{"key":"42714_CR29","doi-asserted-by":"publisher","first-page":"7041","DOI":"10.1128\/jvi.00357-07","volume":"81","author":"M Faber","year":"2007","unstructured":"Faber, M. et al. Dominance of a Nonpathogenic Glycoprotein Gene over a Pathogenic Glycoprotein Gene in Rabies Virus. Journal of Virology 81, 7041\u20137047, https:\/\/doi.org\/10.1128\/jvi.00357-07 (2007).","journal-title":"Journal of Virology"},{"key":"42714_CR30","unstructured":"European Medicins Agency. Rabitec: European Public Assessment Report - Summary for the public. (EMA, London, United Kingdom, 2017)."},{"key":"42714_CR31","doi-asserted-by":"publisher","DOI":"10.1111\/zph.12487","author":"EJ Mendoza","year":"2018","unstructured":"Mendoza, E. J., Warner, B., Kobinger, G., Ogden, N. H. & Safronetz, D. Baited vaccines: A strategy to mitigate rodent-borne viral zoonoses in humans. Zoonoses and public health. https:\/\/doi.org\/10.1111\/zph.12487 (2018).","journal-title":"Zoonoses and public health"},{"key":"42714_CR32","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/j.vaccine.2017.12.076","volume":"36","author":"A Vos","year":"2018","unstructured":"Vos, A. et al. An assessment of shedding with the oral rabies virus vaccine strain SPBN GASGAS in target and non-target species. Vaccine 36, 811\u2013817, https:\/\/doi.org\/10.1016\/j.vaccine.2017.12.076 (2018).","journal-title":"Vaccine"},{"key":"42714_CR33","doi-asserted-by":"crossref","unstructured":"Vos, A., Pommerening, E., Neubert, L., Kachel, S. & Neubert, A. Safety Studies of the Oral Rabies Vaccine SAD B19 in Striped Skunk (Mephitis mephitis). Journal of Wildlife Diseases. Vol. 38 (2002).","DOI":"10.7589\/0090-3558-38.2.428"},{"key":"42714_CR34","doi-asserted-by":"publisher","first-page":"e0003953","DOI":"10.1371\/journal.pntd.0003953","volume":"9","author":"TF M\u00fcller","year":"2015","unstructured":"M\u00fcller, T. F., Schr\u00f6der, R., Wysocki, P., Mettenleiter, T. C. & Freuling, C. M. Spatio-temporal Use of Oral Rabies Vaccines in Fox Rabies Elimination Programmes in Europe. Plos Neglected Tropical Diseases 9, e0003953, https:\/\/doi.org\/10.1371\/journal.pntd.0003953 (2015).","journal-title":"Plos Neglected Tropical Diseases"},{"key":"42714_CR35","unstructured":"Committee for Medicinal Products for Veterinary Use. CVMP assessment report for Rabitec (EMEA\/V\/C\/004387\/0000) (European Medicines Agency, London, United Kingdom, 2017)."},{"key":"42714_CR36","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3389\/fvets.2018.00091","volume":"5","author":"S Ortmann","year":"2018","unstructured":"Ortmann, S. et al. In Vivo Safety Studies With SPBN GASGAS in the Frame of Oral Vaccination of Foxes and Raccoon Dogs Against Rabies. Frontiers in Veterinary Science 5, 91, https:\/\/doi.org\/10.3389\/fvets.2018.00091 (2018).","journal-title":"Frontiers in veterinary science"},{"key":"42714_CR37","doi-asserted-by":"publisher","first-page":"163","DOI":"10.2460\/javma.240.2.163","volume":"240","author":"AA Roess","year":"2012","unstructured":"Roess, A. A. et al. National surveillance for human and pet contact with oral rabies vaccine baits, 2001-2009. Journal of the American Veterinary Medical Association 240, 163\u2013168, https:\/\/doi.org\/10.2460\/javma.240.2.163 (2012).","journal-title":"Journal of the American Veterinary Medical Association"},{"key":"42714_CR38","first-page":"267","volume":"62","author":"F Kellog","year":"2013","unstructured":"Kellog, F. et al. Human contacts with oral rabies vaccine baits distributed for wildlife rabies management - Ohio, 2012. Morbidity and Mortality Weekly Report 62, 267\u2013269 (2013).","journal-title":"Morbidity and Mortality Weekly Report"},{"key":"42714_CR39","doi-asserted-by":"publisher","unstructured":"Etheart, M. D. et al. Effect of counselling on health-care-seeking behaviours and rabies vaccination adherence after dog bites in Haiti, 2014\u201315: a retrospective follow-up survey. The Lancet Global Health 5, e1017\u2013e1025, https:\/\/doi.org\/10.1016\/S2214-109X(17)30321-2 (2017).","DOI":"10.1016\/S2214-109X(17)30321-2"},{"key":"42714_CR40","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/0021-9991(76)90041-3","volume":"22","author":"DT Gillespie","year":"1976","unstructured":"Gillespie, D. T. A general method for numerically simulating the stochastic time evolution of coupled chemical reactions. Journal of Computational Physics 22, 403\u2013434, https:\/\/doi.org\/10.1016\/0021-9991(76)90041-3 (1976).","journal-title":"Journal of Computational Physics"},{"key":"42714_CR41","unstructured":"Vos, A., Aylan, O. & Estrada, R. In Proceedings of the seventh Southern and Eastern African Rabies Group\/World Health Organization Meeting. 125\u2013130."},{"key":"42714_CR42","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3389\/fvets.2017.00009","volume":"4","author":"RM Wallace","year":"2017","unstructured":"Wallace, R. M., Undurraga, E. A., Blanton, J. D., Cleaton, J. & Franka, R. Elimination of Dog-Mediated Human Rabies Deaths by 2030: Needs Assessment and Alternatives for Progress Based on Dog Vaccination. Frontiers in veterinary science 4, 9, https:\/\/doi.org\/10.3389\/fvets.2017.00009 (2017).","journal-title":"Frontiers in veterinary science"},{"key":"42714_CR43","unstructured":"Leukemia and Lymphoma Society. Facts and statistics, http:\/\/www.lls.org\/facts-and-statistics\/ (2018)."},{"key":"42714_CR44","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.idc.2014.05.001","volume":"28","author":"J Fettig","year":"2014","unstructured":"Fettig, J., Swaminathan, M., Murrill, C. S. & Kaplan, J. E. Global Epidemiology of HIV. Infectious disease clinics of North America 28, 323\u2013337, https:\/\/doi.org\/10.1016\/j.idc.2014.05.001 (2014).","journal-title":"Infectious disease clinics of North America"},{"key":"42714_CR45","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1097\/QAI.0b013e318293ae48","volume":"63","author":"K Kranzer","year":"2013","unstructured":"Kranzer, K., Lawn, S. D., Johnson, L. F., Bekker, L.-G. & Wood, R. Community viral load and CD4 count distribution among people living with HIV in a South African township: implications for treatment as prevention. Journal of acquired immune deficiency syndromes (1999) 63, 498\u2013505, https:\/\/doi.org\/10.1097\/QAI.0b013e318293ae48 (2013).","journal-title":"Journal of acquired immune deficiency syndromes (1999)"},{"key":"42714_CR46","doi-asserted-by":"publisher","first-page":"e70126","DOI":"10.1371\/journal.pone.0070126","volume":"8","author":"A Malaza","year":"2013","unstructured":"Malaza, A., Mossong, J., B\u00e4rnighausen, T., Viljoen, J. & Newell, M.-L. Population-Based CD4 Counts in a Rural Area in South Africa with High HIV Prevalence and High Antiretroviral Treatment Coverage. PloS one 8, e70126, https:\/\/doi.org\/10.1371\/journal.pone.0070126 (2013).","journal-title":"PloS one"},{"key":"42714_CR47","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1007\/s10875-014-0102-8","volume":"34","author":"L Kobrynski","year":"2014","unstructured":"Kobrynski, L., Powell, R. W. & Bowen, S. Prevalence and morbidity of primary immunodeficiency diseases, United States 2001-2007. Journal of clinical immunology 34, 954\u2013961, https:\/\/doi.org\/10.1007\/s10875-014-0102-8 (2014).","journal-title":"Journal of clinical immunology"},{"key":"42714_CR48","unstructured":"Carnell, R. lhs: Latin Hypercube Samples. R package version 0.16, https:\/\/CRAN.R-project.org\/package=lhs (2018)."},{"key":"42714_CR49","unstructured":"Pujol, G., Iooss, B. & Janon, A. Sensitivity: Global Sensitivity Analysis of Model Outputs. R package version 1.15.0, https:\/\/CRAN.R-project.org\/package=sensitivity (2017)."},{"key":"42714_CR50","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.joad.2016.08.019","volume":"5","author":"T Babazadeh","year":"2016","unstructured":"Babazadeh, T. et al. Epidemiology of acute animal bite and the direct cost of rabies vaccination. Journal of Acute Disease 5, 488\u2013492, https:\/\/doi.org\/10.1016\/j.joad.2016.08.019 (2016).","journal-title":"Journal of Acute Disease"},{"key":"42714_CR51","doi-asserted-by":"publisher","unstructured":"Petersen, B. W. & Rupprecht. C. E. Human Rabies Epidemiology and Diagnosis, Non-Flavivirus Encephalitis, Sergey Tkachev, IntechOpen, Available from: https:\/\/www.intechopen.com\/books\/non-flavivirus-encephalitis\/human-rabies-epidemiology-and-diagnosis, https:\/\/doi.org\/10.5772\/21708 (2011).","DOI":"10.5772\/21708"},{"key":"42714_CR52","first-page":"360","volume":"117","author":"A Vos","year":"2004","unstructured":"Vos, A. et al. The spatial and temporal disappearance of different oral rabies vaccine baits. Berliner und Munchener tierarztliche Wochenschrift 117, 360\u2013366 (2004).","journal-title":"Berliner und Munchener tierarztliche Wochenschrift"},{"key":"42714_CR53","doi-asserted-by":"publisher","first-page":"222","DOI":"10.7589\/0090-3558-40.2.222","volume":"40","author":"BF Blackwell","year":"2004","unstructured":"Blackwell, B. F. et al. Exposure time of oral rabies vaccine baits relative to baiting density and raccoon population density. Journal of wildlife diseases 40, 222\u2013229, https:\/\/doi.org\/10.7589\/0090-3558-40.2.222 (2004).","journal-title":"Journal of wildlife diseases"},{"key":"42714_CR54","first-page":"428","volume":"109","author":"A Vos","year":"2002","unstructured":"Vos, A. & Neubert, A. Thermo-stability of the oral rabies virus vaccines SAD B19 and SAD P5\/88. DTW. Deutsche tierarztliche Wochenschrift 109, 428\u2013432 (2002).","journal-title":"DTW. Deutsche tierarztliche Wochenschrift"},{"key":"42714_CR55","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1111\/jtm.12024","volume":"20","author":"ES Jentes","year":"2013","unstructured":"Jentes, E. S. et al. The global availability of rabies immune globulin and rabies vaccine in clinics providing direct care to travelers. Journal of travel medicine 20, 148\u2013158, https:\/\/doi.org\/10.1111\/jtm.12024 (2013).","journal-title":"Journal of travel medicine"},{"key":"42714_CR56","unstructured":"Human vaccinia infection after contact with a raccoon rabies vaccine bait - Pennsylvania, 2009. MMWR. Morbidity and mortality weekly report 58, 1204\u20131207 (2009)."},{"key":"42714_CR57","doi-asserted-by":"crossref","unstructured":"McGuill, M. W et al. Human contact with bait containing vaccine for control of rabies in wildlife. Journal of the American Veterinary Medical Association. Vol. 213 (1998).","DOI":"10.2460\/javma.1998.213.10.1413"},{"key":"42714_CR58","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1056\/NEJMoa010560","volume":"345","author":"CE Rupprecht","year":"2001","unstructured":"Rupprecht, C. E. et al. Human infection due to recombinant vaccinia-rabies glycoprotein virus. New England Journal of Medicine. 345, 582\u2013586, https:\/\/doi.org\/10.1056\/NEJMoa010560 (2001).","journal-title":"N Engl J Med"},{"key":"42714_CR59","first-page":"1204","volume":"58","author":"Centers for Disease Control and Prevention (CDC)","year":"2009","unstructured":"Centers for Disease Control and Prevention (CDC). Human vaccinia infection after contact with a raccoon rabies vaccine bait\u2014Pennsylvania. MMWR. Morbidity and mortality weekly report 58, 1204\u20131207 (2009).","journal-title":"MMWR. Morbidity and mortality weekly report"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-42714-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-42714-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-42714-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T10:14:21Z","timestamp":1721211261000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-42714-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,1]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["42714"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-42714-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,1]]},"assertion":[{"value":"28 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.R.H., J.B.,\u00a0R.C., E.G.P., J.C. and R.W. declare no competing interests.\u00a0A.V. is a full-time employee of a pharmaceutical company, IDT Biologika GmbH, which manufactures oral rabies vaccine baits. T.M. from the Friedrich-Loeffler-Institute received funding from IDT Biologika GmbH in the frame of a research cooperation for research into mechanisms of oral rabies vaccination and resulting immunity.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"6783"}}